_256_384.jpg)
News | September 17, 2021
Promising prospects for Indian pharma: CLSA
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Subscribe To Our Newsletter & Stay Updated
